Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytokinetics (CYTK) Non-Current Assets: 2009-2025

Historic Non-Current Assets for Cytokinetics (CYTK) over the last 16 years, with Sep 2025 value amounting to $459.2 million.

  • Cytokinetics' Non-Current Assets rose 10.00% to $459.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $459.2 million, marking a year-over-year increase of 10.00%. This contributed to the annual value of $293.7 million for FY2024, which is 49.66% up from last year.
  • According to the latest figures from Q3 2025, Cytokinetics' Non-Current Assets is $459.2 million, which was up 35.42% from $339.1 million recorded in Q2 2025.
  • In the past 5 years, Cytokinetics' Non-Current Assets ranged from a high of $459.2 million in Q3 2025 and a low of $143.9 million during Q1 2021.
  • In the last 3 years, Cytokinetics' Non-Current Assets had a median value of $293.7 million in 2024 and averaged $292.8 million.
  • Its Non-Current Assets has fluctuated over the past 5 years, first soared by 1,377.53% in 2021, then tumbled by 42.37% in 2022.
  • Cytokinetics' Non-Current Assets (Quarterly) stood at $305.6 million in 2021, then dropped by 28.16% to $219.6 million in 2022, then decreased by 10.62% to $196.3 million in 2023, then soared by 49.66% to $293.7 million in 2024, then increased by 10.00% to $459.2 million in 2025.
  • Its Non-Current Assets stands at $459.2 million for Q3 2025, versus $339.1 million for Q2 2025 and $308.0 million for Q1 2025.